Skip to content

Journal of Psychopharmacology

ISSN 0269-8811, 1461-7285

521 papers in the library · 34,708 citations · publishing 1992-2026

Papers

Sort Most recent Most cited

The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women

Journal of Psychopharmacology December 1, 2018 Elena Argento, Melissa Braschel, Zach Walsh et al.

Background/aims: Given high rates of depression and suicide among marginalized women, and increasing calls to integrate trauma-informed biomedical and community-led structural interventions, this study longitudinally examines the potential moderating effect of psychedelic use on the relationship between other illicit drug use and suicide risk. Methods: Data (2010–2017) were drawn from a...

Clozapine attenuates mitochondrial burdens and abnormal behaviors elicited by phencyclidine in mice via inhibition of p47 phox; Possible involvements of phosphoinositide 3-kinase/Akt signaling.

Journal of Psychopharmacology November 2018 Hai-Quyen Tran, Se J Park, Eun-Joo Shin et al.

Oxidative stress and mitochondrial dysfunction have been implicated in the pathophysiology of schizophrenia. We investigated whether antipsychotic clozapine modulates nicotinamide adenine dinucleotide phosphate oxidase and mitochondrial burdens induced by phencyclidine in mice. We examined the effect of clozapine on nicotinamide adenine dinucleotide phosphate oxidase activation, mitochondrial...

DOI: 10.1177/0269881118795244 (opens in new tab) Full text (opens in new tab) Clozapine Mitochondria Oxidative stress P47phox knockout mice +3

Rapid effectiveness of intravenous ketamine for ultraresistant depression in a clinical setting and evidence for baseline anhedonia and bipolarity as clinical predictors of effectiveness.

Journal of Psychopharmacology October 2018 Rejish K Thomas, Glen B. Baker, John Lind et al.

Intravenous ketamine has been established as an efficacious and safe treatment, with transient effect, for treatment-resistant depression. However, the effectiveness of intravenous ketamine in non-research settings and with ultraresistant depression patients remains understudied. This study aims to measure the response and remission rates in ultraresistant depression patients in a clinical...

The effect of route of administration on the enantioselective pharmacokinetics of ketamine and norketamine in rats.

Journal of Psychopharmacology October 2018 Martin Le Nedelec, Paul Glue, Helen Winter et al.

Ketamine has been shown to produce a rapid and potent antidepressant response in patients with treatment-resistant depression. Currently ketamine is most commonly administered as a 40-minute intravenous infusion, though it is unknown whether this is the optimal route of administration. To determine the plasma concentration time course of the R- and S-enantiomers of ketamine and norketamine...

Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression

Journal of Psychopharmacology September 27, 2018 Yanling Zhou, Wei Zheng, Weijian Liu et al. 74 citations

BACKGROUND: Ketamine has proven to have rapid, robust antidepressant effects on treatment-resistant depression. However, whether repeated ketamine infusions would cause short-and long-term neurocognitive impairments was not clear. Our aims were to investigate the neurocognitive effects of six ketamine infusions and to examine the association between these infusions and the antidepressant...

The evolutionary old forebrain as site of action to develop new psychotropic drugs

Journal of Psychopharmacology September 26, 2018 Anton J. M. Loonen, Svetlana А. Ivanova 39 citations

BACKGROUND: Previously, the authors have developed a model of how reward-seeking and distress- avoiding behaviour is regulated by the human brain. The forebrain's evolution in vertebrates was taken as a starting point. AIMS: The authors want to inspire colleagues to study in particular the pharmacological effects on the described ancient forebrain structures in order to modify specific symptoms...

Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016

Journal of Psychopharmacology September 5, 2018 James B. Leonard, Bruce D. Anderson, Wendy Klein‐schwartz 85 citations

Background: Lysergic acid diethylamide (LSD) and psilocybin are serotonergic hallucinogens that are used primarily for recreational abuse. Small studies evaluated the efficacy of LSD and psilocybin for several psychiatric conditions. There are limited safety or toxicity data for either of these substances, especially in large populations. Methods: This was a retrospective analysis of...

DOI: 10.1177/0269881118793086 (opens in new tab) Psilocybin Hallucinogen Mushroom poisoning Poison control

The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption.

Journal of Psychopharmacology July 1, 2018 Alan K. Davis, Joseph P Barsuglia, Rafael Lancelotta et al. 137 citations

5-Methoxy- N,N-dimethyltryptamine (5-MeO-DMT) is a psychoactive compound found in several plants and in high concentrations in Bufo alvarius toad venom. Synthetic, toad, and plant-sourced 5-MeO-DMT are used for spiritual and recreational purposes and may have psychotherapeutic effects. However, the use of 5-MeO-DMT is not well understood. Therefore, we examined patterns of use, motivations for...

DOI: 10.1177/0269881118769063 (opens in new tab) Full text (opens in new tab) 5-Methoxy-N,N-Dimethyltryptamine 5-MEO-DMT 5-Methoxy-N Psychoactive tryptamines Compound +9

Psychedelics and hypnosis: Commonalities and therapeutic implications.

Journal of Psychopharmacology July 1, 2018 Clément E Lemercier, Devin B. Terhune

Recent research on psychedelics and hypnosis demonstrates the value of both methods in the treatment of a range of psychopathologies with overlapping applications and neurophenomenological features. The potential of harnessing the power of suggestion to influence the phenomenological response to psychedelics toward more therapeutic action has remained unexplored in recent research and thereby...

DOI: 10.1177/0269881118780714 (opens in new tab) Full text (opens in new tab) Consciousness Hypnosis Psychedelics Psychotherapy +1

High dose psilocybin is associated with positive subjective effects in healthy volunteers

Journal of Psychopharmacology June 27, 2018 Christopher R. Nicholas, Kelsey M. Henriquez, Michele Gassman et al. 85 citations

Aim: The aim of the current study was to investigate the relationship between escalating higher doses of psilocybin and the potential psilocybin occasioned positive subjective effects. Methods: Healthy participants ( n=12) were given three escalating doses of oral psilocybin (0.3 mg/kg; 0.45 mg/kg; 0.6 mg/kg) or (18.8–36.6 mg; 27.1–54.0 mg; 36.3–59.2 mg) a minimum of four weeks apart in a...

Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts

Journal of Psychopharmacology June 25, 2018 Tehseen Noorani, Albert Garcia‐romeu, Thomas Cody Swift et al. 285 citations

Background: Recent pilot trials suggest feasibility and potential efficacy of psychedelic-facilitated addiction treatment interventions. Fifteen participants completed a psilocybin-facilitated smoking cessation pilot study between 2009 and 2015. Aims: The aims of this study were as follows: (1) to identify perceived mechanisms of change leading to smoking cessation in the pilot study; (2) to...

DOI: 10.1177/0269881118780612 (opens in new tab) Addiction Psilocybin Qualitative research Smoking cessation +7

Impure but not inactive: Behavioral pharmacology of dibenzylpiperazine, a common by-product of benzylpiperazine synthesis

Journal of Psychopharmacology June 18, 2018 Sean B. Dolan, Ritu A. Shetty, Michael J. Forster et al. 2 citations

BACKGROUND: Substituted piperazines comprise a substantial proportion of the novel psychoactive substance market. Among the most widely abused piperazine compounds are meta-chlorophenylpiperazine (mCPP), tri-fluoromethylphenylpiperazine (TFMPP), and, especially, benzylpiperazine (BZP), which are commonly incorporated, either alone or in combination, in illicit "party pills" or "ecstasy"...

Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders.

Journal of Psychopharmacology June 2018 Paul Glue, Shona Neehoff, Natalie J. Medlicott et al.

In this maintenance treatment study, we sought to evaluate the effect on anxiety ratings, safety and tolerability of 3 months of weekly ketamine in 20 patients with treatment-refractory DSM IV generalised anxiety disorder (GAD) and/or social anxiety disorder (SAD), and subsequent assessment of remission post-treatment. This was an uncontrolled open-label study in 20 patients who had been...

DOI: 10.1177/0269881118762073 (opens in new tab) Full text (opens in new tab) Ketamine Generalised anxiety disorder Maintenance treatment Social anxiety disorder

Psychedelic use and intimate partner violence: The role of emotion regulation

Journal of Psychopharmacology May 29, 2018 Michelle S. Thiessen, Zach Walsh, Brian M. Bird et al. 58 citations

Background: Recent evidence suggests that psychedelic use predicts reduced perpetration of intimate partner violence among men involved in the criminal justice system. However, the extent to which this association generalizes to community samples has not been examined, and potential mechanisms underlying this association have not been directly explored. Aims: The present study examined the...

DOI: 10.1177/0269881118771782 (opens in new tab) Domestic violence Poison control Injury prevention Intimate partner +1

Are ecstasy induced serotonergic alterations overestimated for the majority of users?

Journal of Psychopharmacology May 7, 2018 Balázs Szigeti, Adam Winstock, David Erritzøe et al. 17 citations

BACKGROUND: Neuroimaging studies imply that the regular use of ±3,4-methylenedioxymethamphetamine (MDMA), the major constituent of ecstasy pills, alters the brain's serotonergic system in a dose-dependent manner. However, the relevance of these findings remains unclear due to limited knowledge about the ecstasy/MDMA use pattern of real-life users. AIMS: We examined the representativeness of...

Repeated intranasal ketamine for treatment-resistant depression - the way to go? Results from a pilot randomised controlled trial.

Journal of Psychopharmacology April 2018 Verònica Gálvez, Adrienne Li, Christina Huggins et al.

Ketamine research in depression has mostly used intravenous, weight-based approaches, which are difficult to translate clinically. Intranasal (IN) ketamine is a promising alternative but no controlled data has been published on the feasibility, safety and potential efficacy of repeated IN ketamine treatments. This randomised, double-blind, placebo-controlled pilot study compared a 4-week course...

Neuroimaging meta-analysis of cannabis use studies reveals convergent functional alterations in brain regions supporting cognitive control and reward processing.

Journal of Psychopharmacology March 2018 Julio A Yanes, Michael C Riedel, Kimberly L Ray et al.

Lagging behind rapid changes to state laws, societal views, and medical practice is the scientific investigation of cannabis's impact on the human brain. While several brain imaging studies have contributed important insight into neurobiological alterations linked with cannabis use, our understanding remains limited. Here, we sought to delineate those brain regions that consistently demonstrate...

Medicinal cannabis (Bedrolite) substitution therapy in inpatients with a psychotic disorder and a comorbid cannabis use disorder: A case series.

Journal of Psychopharmacology March 2018 Regi Schipper, Mathilde Dekker, Lieuwe de Haan et al.

Cannabis use disorders are frequently comorbid in patients with a psychotic disorder and are associated with worse outcomes. To date there are no proven effective strategies to achieve cannabis abstinence in this population. An alternative for abstinence might be harm reduction, i.e. replacing the use of street cannabis with high tetrahydrocannabinol and low cannabidiol levels by medicinal...

Psychedelics and the essential importance of context.

Journal of Psychopharmacology February 15, 2018 Robin Carhart-Harris, Leor Roseman, Eline Haijen et al. 646 citations

Psychedelic drugs are making waves as modern trials support their therapeutic potential and various media continue to pique public interest. In this opinion piece, we draw attention to a long-recognised component of the psychedelic treatment model, namely ‘set’ and ‘setting’ – subsumed here under the umbrella term ‘context’. We highlight: (a) the pharmacological mechanisms of classic...

DOI: 10.1177/0269881118754710 (opens in new tab) Psychedelics Hallucinogens Entheogens Psychedelic compounds +21

Mapping the central effects of (±)-ketamine and traxoprodil using pharmacological magnetic resonance imaging in awake rats.

Journal of Psychopharmacology February 2018 Haiying Tang, Daniel Kukral, Yu-Wen Li et al.

Major depressive disorder is a leading cause of disability globally. Improvements in the efficacy of antidepressant therapy are needed as a high proportion (>40%) of individuals with major depressive disorder fail to respond adequately to current treatments. The non-selective N-methyl-D-aspartate receptor channel blocker, (±)-ketamine, has been reported to produce a rapid and long-lasting...

Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression

Journal of Psychopharmacology January 17, 2018 Taylor Lyons, Robin Carhart-Harris 176 citations

Rationale: Previous research suggests that classical psychedelic compounds can induce lasting changes in personality traits, attitudes and beliefs in both healthy subjects and patient populations. Aim: Here we sought to investigate the effects of psilocybin on nature relatedness and libertarian–authoritarian political perspective in patients with treatment-resistant depression (TRD). Methods:...

DOI: 10.1177/0269881117748902 (opens in new tab) Psilocybin Authoritarianism Dosing Depression economics +3

N,N -dimethyltryptamine and the pineal gland: Separating fact from myth

Journal of Psychopharmacology 2018 David E Nichols 68 citations

The pineal gland has a romantic history, from pharaonic Egypt, where it was equated with the eye of Horus, through various religious traditions, where it was considered the seat of the soul, the third eye, etc. Recent incarnations of these notions have suggested that N,N-dimethyltryptamine is secreted by the pineal gland at birth, during dreaming, and at near death to produce out of body...

The relationships of classic psychedelic use with criminal behavior in the United States adult population

Journal of Psychopharmacology October 17, 2017 Peter S. Hendricks, Michael S Crawford, Karen L. Cropsey et al. 91 citations

Criminal behavior exacts a large toll on society and is resistant to intervention. Some evidence suggests classic psychedelics may inhibit criminal behavior, but the extent of these effects has not been comprehensively explored. In this study, we tested the relationships of classic psychedelic use and psilocybin use per se with criminal behavior among over 480,000 United States adult...

DOI: 10.1177/0269881117735685 (opens in new tab) Psilocybin Hallucinogen Criminal behavior Population +4

The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder

Journal of Psychopharmacology October 17, 2017 Mark J. Niciu, Nicolas D. Iadarola, Dipavo Banerjee et al. 23 citations

BACKGROUND: This study sought to reproduce, in a larger sample, previous findings of a correlation between smaller raw 3-Tesla (3T) hippocampal volumes and improved antidepressant efficacy of ketamine in individuals with major depressive disorder (MDD). A secondary analysis stratified subjects according to functional BDNF rs6265 (val66met) genotype. METHODS: Unmedicated subjects with...

Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors

Journal of Psychopharmacology October 11, 2017 Roland R. Griffiths, Matthew W. Johnson, William A. Richards et al. 528 citations

Psilocybin can occasion mystical-type experiences with participant-attributed increases in well-being. However, little research has examined enduring changes in traits. This study administered psilocybin to participants who undertook a program of meditation/spiritual practices. Healthy participants were randomized to three groups (25 each): (1) very low-dose (1 mg/70 kg on sessions 1 and 2)...